Lung Cancer


Share

Program Content

Activities

  • EVOKE 01
    EVOKE-01: Phase III Trial of Sacituzumab Govitecan vs Docetaxel in Patients With Previously Treated Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2024

    Expires: June 01, 2025

  • CROWN 5 Yr Update
    Phase III CROWN: 5-Yr Update of First-line Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2024

    Expires: June 02, 2025

  • KRYSTAL 12
    KRYSTAL-12: Phase III Trial of Adagrasib vs Docetaxel in Previously Treated Advanced KRASG12C- Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • LAURA: Osimertinib Consolidation
    LAURA: Phase III Trial of Osimertinib vs Placebo After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • ADRIATIC
    ADRIATIC: Phase III Trial of Consolidation Therapy With Durvalumab for Limited-Stage Small-Cell Lung Cancer
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • PALOMA-3 SC Amivantamab
    PALOMA-3: Phase III Noninferiority Trial of SC Amivantamab vs IV Amivantamab Each With Lazertinib in Progressive Advanced EGFR-Mutated NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2024

    Expires: June 03, 2025

  • DESTINY Lung02 Final Analysis
    DESTINY-Lung02: Final Analysis of Trastuzumab Deruxtecan in Previously Treated HER2-Mutated Metastatic NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • Beamion LUNG 1
    Beamion LUNG-1 Phase Ia/Ib Study: Updated Results of HER2 TKI Zongertinib in Patients With Advanced NSCLC or Other Solid Tumors With HER2 Aberrations
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • WU KONG1
    WU-KONG1: Primary Analysis of a Phase II Study of Sunvozertinib in Patients With Previously Treated Advanced NSCLC and an EGFR Exon 20 Insertion Mutations
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2024

    Expires: June 05, 2025

  • REACH PC
    REACH PC: A Comparison of Efficacy of Telehealth vs In-Person Visits for Delivery of Early Palliative Care for Patients With Advanced NSCLC
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2024

    Expires: June 06, 2025

  • ASCO to Clinic: Lung Cancers
    Conference to Clinic: Lung Cancers
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 21, 2024

    Expires: June 20, 2025

  • ASCO 2024 lung cancer WC
    Conference to Clinic: Lung Cancer
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 02, 2024

    Expires: July 01, 2025

  • ASCO 2024: Lung Cancer
    Conference to Clinic: Expert Analysis of the Top Abstracts in Lung Cancer From the 2024 Oncology Meeting in Chicago
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 23, 2024

    Expires: February 22, 2025

Faculty

cover img faculity

Natasha Leighl, MD, MMSc, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

cover img faculity

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.